{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-220691","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2026-05-13T12:32:07+00:00","discovered_at":"2026-05-13T12:35:08.231562+00:00","generated_at":"2026-05-13T12:35:32.178335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track","bullets":["Cash, equivalents, and investments of $174.8M as of March 31, 2026; operating runway extended into 2028.","Total revenue $1.3M from Ono Pharmaceutical collaboration; total operating expenses $34.3M (R&D $24.7M, G&A $9.6M, including $3.9M stock-based comp).","RECLAIM-LN Phase 2 potentially registrational trial of FT819 for lupus nephritis on track to initiate in H2 2026; approximately 53 patients planned.","FT819 selected into FDA CDRP program for enhanced CMC engagement; also has RMAT designation for SLE.","FT839 IND planned H2 2026 for autoimmune diseases; FT836 Phase 1 enrolling solid tumor patients with no ICANS/GvHD/CRS or DLTs observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-220691","json":"https://secwatch.observer/filing/0001193125-26-220691.json","markdown":"https://secwatch.observer/filing/0001193125-26-220691.md","text":"https://secwatch.observer/filing/0001193125-26-220691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/0001193125-26-220691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:35:32.178335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"927363119f5358488642da78a5ccaa9caee0ba8e","claim":"FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, Fate Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/0001193125-26-220691-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}